Labomar acquires Finland-based Pharmia Holding Oy from CapMan to strengthen European probiotics and medical devices portfolio

Labomar acquires Finland-based Pharmia Holding Oy from CapMan to strengthen European probiotics and medical devices portfolio

(IN BRIEF) CapMan Buyout has sold Pharmia Holding Oy, the leading Nordic contract manufacturer of dietary supplements and medical devices, to Labomar, an Italy-based European group owned by Charterhouse Capital Partners. Since CapMan’s investment in 2021, Pharmia has grown into a €20 million turnover company with 85 employees, driven by a strategic focus on medical devices, probiotics, and strengthened R&D capabilities. CEO Petteri Laaksomo welcomed the acquisition, highlighting the alignment with Labomar’s expertise and vision. Labomar CEO Walter Bertin said Pharmia’s addition enhances the group’s presence in the Nordics and consolidates its position in probiotics, creating synergies for further growth. The deal positions Pharmia to continue its innovation journey with broader international support.

(PRESS RELEASE) HELSINKI, 2-Oct-2025 — /EuropaWire/ — CapMan Buyout has completed the sale of Pharmia Holding Oy, a Finnish contract manufacturer specializing in dietary supplements and medical devices, to Labomar, a European leader in food supplements, medical devices, and functional cosmetics.

CapMan first invested in Pharmia in 2021 and has since supported the company’s expansion in the Nordics, strengthening its market position through targeted growth in medical devices and probiotics. Under CapMan’s ownership, Pharmia enhanced its research and development capabilities, improved operational efficiency, and today stands as the leading contract manufacturer in its segment in the Nordic region. The company currently employs 85 people and generates annual revenues of approximately €20 million.

Anders Björkell, Partner at CapMan Buyout, commented: “During our ownership, Pharmia successfully delivered on its growth strategy. I extend my thanks to the management team, employees, and my board colleagues for their efforts in making this a successful investment. We are confident that Labomar is the right partner to continue Pharmia’s growth journey.”

Petteri Laaksomo, CEO of Pharmia, added: “We are grateful to CapMan for their support in recent years. Joining the Labomar family is an exciting step that strengthens our ability to develop and deliver high-quality dietary supplements and medical devices. Labomar shares our values and vision, and together we will expand our footprint in the Nordic region while driving innovation and value creation for our customers.”

Headquartered in Italy and backed by Charterhouse Capital Partners, Labomar has operations in Spain and Canada and is recognized as a key player in the European health and wellness industry. Walter Bertin, Founder and CEO of Labomar, noted: “Pharmia is a well-structured company with a strategy and culture aligned to ours. Its strong expertise and team will not only reinforce our presence in the Nordic market but also enhance our position in probiotics, one of our priority sectors. This acquisition is a significant step in building synergies and broadening our portfolio.”

The transaction strengthens Labomar’s European footprint and consolidates its presence in the growing market for probiotics and dietary supplements, while ensuring Pharmia gains new momentum under the ownership of a larger, international group.

For more information, please contact:

Anders Björkell, Partner, CapMan Buyout, +358 40 537 7566

Petteri Laaksomo, CEO, Pharmia, +358 50 552 5255

About CapMan

CapMan is a leading Nordic private asset expert with an active approach to value creation and 6.5 billion euros in assets under management. As one of the private equity pioneers in the Nordics we have developed hundreds of companies and assets creating significant value for over three decades. Our objective is to provide attractive returns and innovative solutions to investors by enabling change across our portfolio companies. An example of this is greenhouse gas reduction targets that we have set under the Science Based Targets initiative in line with the 1.5°C scenario and our commitment to net-zero GHG emissions by 2040. We have a broad presence in the unlisted market through our local and specialised teams. Our investment strategies cover real estate and infrastructure assets, real asset debt, natural capital and minority and majority investments in portfolio companies. We also provide wealth management solutions. Altogether, CapMan employs around 200 professionals in Helsinki, Jyväskylä, Stockholm, Copenhagen, Oslo, London, Luxembourg, and Düsseldorf. We are listed on Nasdaq Helsinki since 2001. Learn more at www.capman.com.

About Pharmia

Pharmia is Finland’s leading contract manufacturer specialised in the development and manufacture of food supplements and medical devices (CE-marked products). Pharmia enhances people’s well-being by creating innovative solutions for their customers, which they produce with a concept “from idea to product”. Pharmia’s passion for well-being guides them to be more than just a contract manufacturer – they are a partner that implements and enables their customers’ success. https://pharmia.fi/en/.

SOURCE: CapMan